T2 Biosystems Q1 sepsis revenue up 25% YoY to $2.1M; debt cut 79% to $10.5M

T2 Biosystems, Inc.

2024-Q1 EPS reported -$2.66 revenue$2,061,000

Q1 sepsis product revenue $2.1M (+25% YoY); net loss $13.5M ($2.66/sh) vs $18M loss prior year.
Converted $30M of term loan debt for equity; total debt reduced from $50.5M to $10.5M (79% reduction).
Reiterated FY2024 sepsis product revenue guidance of $10M-$11M (49%-64% growth).
Cash $6.2M at March 31, 2024; raised $2.2M via ATM in Q1.
FDA 510(k) clearance for expanded T2Bacteria Panel; T2Lyme and T2Resistance panels advancing toward 3Q 2024.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

T2 Biosystems, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $13.5 million, EPS $2.66 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $2.1 million
Net income: $13.5 million
EPS: $2.66 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights • Achieved first quarter 2024 sepsis product revenue of $2.1 million, representing growth of 25% compared to the prior year period and sequential growth of 23% compared to the fourth quarter of 2023, led by T2Candida Panel sales and strong

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

T2 Biosystems, Inc. entered into Securities Purchase Agreement with CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P. valued at $15.0 million (effective 2024-05-03).

Action: entry
Agreement: equity purchase
Counterparty: CRG Partners III L.P., CRG Partners III - Parallel Fund "A" L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund "B" (Cayman) L.P.
Value: $15.0 million
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, the Company entered into a Securities Purchase Agreement (the “ SPA ”) with CRG Partners III L.P., CRG Partners III - Parallel Fund “A” L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III Parallel Fund “B” (Cayman) L.P. (collectively in such capacity, the “ Lenders ” or the “ Purchasers ”) pursuant to which the Company issued to the Lenders in a private placement offering 4,748,335 shares (the “ Shares ”) of the Company’s common stock in exchange for the Lenders surrendering for cancellation $15.0 million of outstanding loans

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

T2 Biosystems, Inc. entered into Consent and Amendment No. 11 to Term Loan Agreement with Administrative Agent and Lenders under the Loan Agreement (effective 2024-05-03).

Action: entry
Agreement: credit facility
Counterparty: Administrative Agent and Lenders under the Loan Agreement
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, the Company entered into the Consent and Amendment No. 11 to Term Loan Agreement (“ Consent No. 11 ”) to the Loan Agreement. Consent No. 11 provides for, among other things, (i) the consent of the Administrative Agent and the Lenders (who constitute all of the lenders under the Loan Agreement) to the Exchange and (ii) an amendment to the “Change of Control” definition

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-132060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.